カジノ シークレット 勝て ないl Subscribes for Shares of PeptiStar in Private Placement
in Efforts to Enhance High-Purity Long-Chain gRNA Supply Capacity

Nov. 11, 2024

カジノ シークレット 勝て ないl Co., Ltd. (“カジノ シークレット 勝て ないl”) is pleased to announce that it has acquired shares of PeptiStar Inc. (“PeptiStar”) in a private placement. The investment has been completed. Through this capital alliance, カジノ シークレット 勝て ないl will work to further enhance its capacity to ensure a stable supply of high-purity long-chain guide RNA (gRNA) ^*1, while integrating カジノ シークレット 勝て ないl’s and PeptiStar’s technologies to meet diversifying customer needs.

PeptiStar was founded in 2017 to engage in the research and development, manufacturing, and sales of peptide pharmaceutical active ingredients *². Leveraging its extensive expertise, PeptiStar entered the business of contract manufacturing of nucleic acid drug substances *³ in 2021.

カジノ シークレット 勝て ないl began its nucleic acid drug substance contract manufacturing business in 2013. The Company established the world’s first technology to chemically synthesize and produce at scale the high-purity gRNA necessary for genome editing therapies *⁴, and, in August 2023, started operations at a new manufacturing plant in Oita, Japan. Through these efforts, カジノ シークレット 勝て ないl has enhanced its gRNA contract manufacturing capacity. In addition, to meet increasing demand for gRNA, the Company has recently partnered with PeptiStar to establish a dual-site production system by licensing its large-scale production technology and utilizing PeptiStar’s facilities.

This capital alliance aims to further deepen the partnership between カジノ シークレット 勝て ないl and PeptiStar. Going forward, カジノ シークレット 勝て ないl will work with PeptiStar to advance manufacturing technologies for conjugates that combine nucleic acids and peptides.

カジノ シークレット 勝て ないl will continue to strive to consolidate its position as a frontrunner in the manufacturing of nucleic acid drug substances, particularly high-purity long-chain gRNA, in anticipation of market expansion.

*1 RNA molecules used for the CRISPR Cas9 genome editing technology, designed to target specific DNA sequences. The gRNA guides Cas9, an enzyme that cuts DNA, to the target DNA sequence to edit genomes. It is characterized by having a longer chain than typical nucleic acid pharmaceuticals.
*2 Peptide pharmaceuticals are pharmaceuticals that use peptides (compounds consisting of chains of fewer than 50 amino acids) as active ingredients.
*3 Nucleic acid drugs are pharmaceuticals based on nucleic acids (DNA or RNA), and they can act directly and highly selectively on RNA, which is difficult to target with conventional pharmaceuticals.
*4 World’s first technology to produce at scale gRNA with an approximately 90% purity, as of October 4, 2021, the date of カジノ シークレット 勝て ないl’s news release referenced below. This statement is based on research conducted by カジノ シークレット 勝て ないl.

Reference

News release dated October 4, 2021:カジノ シークレット 勝て ないl to Construct a New Manufacturing Plant for Nucleic Acid Drug Substances at Oita Works in Japan - Established the world's first large-scale production technology for high-purity gRNA for genome editing therapy –

Unlock the Power of Genome Editingカジノ シークレット 出 金 方法 Purity gRNA

Contact

カジノ シークレット 勝て ないl Co., Ltd.
Corporate Communications Dept.
カジノ シークレット 無料 ボーナス Address